Ovid Therapeutics Inc. (OVID)
| Market Cap | 134.50M |
| Revenue (ttm) | 1.45M |
| Net Income (ttm) | -69.28M |
| Shares Out | 70.42M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | 1.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190,431 |
| Open | 1.91 |
| Previous Close | 1.88 |
| Day's Range | 1.87 - 1.94 |
| 52-Week Range | 1.65 - 4.42 |
| Beta | 1.58 |
| Analysts | Buy |
| Price Target | 4.79 (+150.8%) |
| Earnings Date | May 12, 2022 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is 4.79, which is an increase of 150.79% from the latest price.
News
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of p...
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve th...
3 Biotech Stocks Under $10 to Add to Your Buy List
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on In...
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and s...
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and s...
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsie...
Healx and Ovid Therapeutics to Enter Strategic Partnership
– Ovid to License Gaboxadol to Healx –
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small molecules targeting the KCC2 transporter, inclu...
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological dis...
A Trio of Magic Formula Stock Picks
In order to increase your chances of beating the market, one method is to choose stocks that rank highly according to the "Magic Formula" criteria.
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
Dr. Michael Poole to Join the Board of Directors
Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological...
Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological ...
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neur...
Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological ...
HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover
The odds of bankrupt HMNY stock getting acquired may be slim, but for these seven other Reddit penny stocks it's definitely a possibility. The post HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a ...
Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions
Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The com...
4 Biotech Penny Stocks To Watch That Are Heating Up This Month
Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Inf...
OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today
Ovid Therapeutics (OVID) stock is soaring higher on Wednesday after announcing a massive deal with Takeda Pharmaceutical (TKPHF). The post OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocket...
Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying
Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...